Home Newsfeeds Needham Downgrades Clarus Therapeutics Hldgs to Hold

Needham Downgrades Clarus Therapeutics Hldgs to Hold

Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.

byBenzinga Newsdesk

August 23, 2022

1 minute read

Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.

C4 Therapeutics Reports FY22 Revenue $31.1M Vs $45.8M YoY; FY22 EPS $(2.62) Vs $(1.82) YoY

By Happy Mohamed

February 23, 8:28 AM

FULL YEAR 2022 FINANCIAL RESULTS Revenue: Total revenue for the year ended December 31, 2022 was $31.1 million, compared to $45.8 million for the year ended December 31, 2021. Total revenue reflects

CCCC

Movers
News

Why Paramount Global Stock Is Moving Lower Wednesday

By Dylan Berman

June 12, 11:04 AM

The CBS News report from Tuesday suggests that National Amusements, which controls Paramount, ended merger discussions with Skydance.

PARA

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

By Avi Kapoor

April 15, 10:00 AM

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also rose, gaining, 0.80% to 5,164.30.

Raymond James Maintains Strong Buy on Ryanair Holdings, Lowers Price Target to $102

By Benzinga Newsdesk

October 5, 7:47 AM

Raymond James analyst Savanthi Syth maintains Ryanair Holdings (NASDAQ:RYAAY) with a Strong Buy and lowers the price target from $112 to $102.

RYAAY

Needham Downgrades Clarus Therapeutics Hldgs to Hold

Related Posts

C4 Therapeutics Reports FY22 Revenue $31.1M Vs $45.8M YoY; FY22 EPS $(2.62) Vs $(1.82) YoY

Why Paramount Global Stock Is Moving Lower Wednesday

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

Raymond James Maintains Strong Buy on Ryanair Holdings, Lowers Price Target to $102